Department of Health
and Human Services (HHS)
and Human Services (HHS)
July 10, 2020
PAR-19-040 - Countermeasures Against Chemical Threats (CounterACT): Optimization of Therapeutic Lead Compounds (U01 Clinical Trial Optional)
National Institute of Neurological Disorders and Stroke (NINDS)
National Eye Institute (NEI)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
National Institute on Drug Abuse (NIDA)
National Institute of Environmental Health Sciences (NIEHS)
The purpose of this notice is to inform interested applicants of a change to the Key Dates for PAR-19-040 "Countermeasures Against Chemical Threats (CounterACT): Optimization of Therapeutic Lead Compounds (U01 Clinical Trial Optional)". The September 9, 2020 receipt date has been changed to October 8, 2020. Changes are show in bold italics below.
Currently Reads:
Part 1. Overview Information
Key Dates
| Application Due Date(s) |
September 10, 2019; September 9, 2020; September 14, 2021, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. |
Modified to Read:
Part 1. Overview Information
Key Dates
| Application Due Date(s) |
September 10, 2019; October 8, 2020; September 14, 2021, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. |
All other aspects of this FOA remain unchanged.
David A. Jett, Ph.D.
National Institute of Neurological Disorder and Stroke (NINDS)
Telephone: 301-496-6035
Email: jettd@ninds.nih.gov